Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.
Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.